GLP-1 medications can reduce hunger by activating receptors involved in the body’s response to food. Semaglutide activates receptors for GLP-1, a hormone the gut releases after eating. Tirzepatide activates receptors for both GLP-1 and GIP, another hormone involved in the response to a meal. Both are options in medically supervised weight-loss treatment.
Some people notice that they feel satisfied with smaller portions or think about food less often. People sometimes call those recurring thoughts “food noise.” Appetite changes vary, though, and a reduction in food noise does not guarantee weight loss.
FDA-approved weight-loss products provide standardized formulations and labeled dosing. In the SURMOUNT-5 trial, adults received once-weekly injections of semaglutide or tirzepatide for 72 weeks. The figures below are average weight loss in that trial, not a prediction of individual results.
Compounded preparations serve a different, patient-specific pathway when a licensed provider documents that an approved product does not adequately meet a patient’s medical needs. Compounded semaglutide and tirzepatide are not FDA-approved, and these trial results do not establish that compounded preparations are equivalent to the approved products.
For medication-selection tradeoffs beyond the trial averages, see Optima’s semaglutide and tirzepatide comparison.
A provider determines whether GLP-1 weight-loss treatment fits your medical history, not your BMI alone. For FDA-approved weight-management products, clinicians commonly consider the following criteria. The BMI figures below are pending verification against the current FDA labels.
The medical encounter gives your provider a chance to check conditions and medicines that a BMI table cannot account for. Your provider can then determine whether treatment is appropriate and which medication pathway, if any, meets your needs.
SURMOUNT-5 measured weight loss with FDA-approved semaglutide and tirzepatide products, not compounded preparations. The registered trial randomized 751 adults with obesity, or overweight and a weight-related condition, who did not have type 2 diabetes. Participants received a maximum tolerated dose of either medication once weekly for 72 weeks.
At week 72, adjusted mean body weight had fallen 20.2% in the tirzepatide group and 13.7% in the semaglutide group, according to a summary of the published results. Those group averages describe outcomes under trial conditions. They cannot predict how much weight an individual will lose. STEP 1 and SURMOUNT-1 figures are not cited here pending primary-source verification.
FDA-approved products provide standardized formulations and labeled dosing. When an approved product does not adequately meet a patient’s documented medical needs, a licensed prescriber may consider a patient-specific compounded preparation. Compounded semaglutide and tirzepatide were not studied in SURMOUNT-5, so its results cannot be assigned to them. The FDA states that compounded GLP-1 drugs are not FDA-approved and do not undergo its premarket review for safety, effectiveness, or quality. They have not been established as equivalent to the approved trial products.
GLP-1 weight-loss injections usually start at a lower dose and increase gradually under a provider’s direction. Gradual increases give you time to see how you tolerate treatment, especially because nausea and other digestive symptoms can occur during dose escalation. The FDA warns that taking too much medication or increasing it too quickly has caused adverse events with compounded GLP-1 injections.
Your timeline depends on the medication, your response, and the dose you can tolerate. Follow your prescription and provider instructions rather than changing the dose or injection frequency yourself. For a closer look at when changes may appear, see Optima’s GLP-1 weight-loss results timeline.
Digestive symptoms are common during GLP-1 weight-loss treatment, particularly while a provider adjusts the dose. FDA guidance identifies nausea, vomiting, and abdominal pain among reported effects.
Provider follow-up gives you a chance to report symptoms before the next dose change. Your provider can then assess how well you tolerate treatment and decide whether to continue or adjust your prescription. If you use a compounded vial, follow your prescribed dose and administration instructions rather than changing the amount or frequency yourself.
For guidance on which symptoms need prompt attention, see Optima Tyler’s GLP-1 side effects and safety guide.
FDA-approved semaglutide and tirzepatide products provide standardized formulations and labeled dosing. Compounding offers a different clinical pathway when a licensed provider determines that an approved product cannot adequately meet a patient’s documented medical needs. For example, a provider may prescribe a patient-specific preparation when a clinically significant difference is needed. FDA compounding policy sets conditions for that decision. Cost or a general preference for customization does not establish medical necessity.
Optima Tyler’s GLP-1 weight-loss care begins with a medical evaluation before a provider considers compounded semaglutide or tirzepatide. Compounded preparations are not FDA-approved, and the FDA does not review them for safety, effectiveness, or quality before they reach patients. Results from trials of approved products therefore cannot establish equivalent results for compounded versions. The FDA advises using compounded GLP-1 drugs only when an approved drug cannot meet a patient’s medical needs.
FDA-approved GLP-1 products provide standardized formulations and labeled dosing. Optima Tyler’s supervised weight-loss program offers patient-specific compounded semaglutide or tirzepatide when a licensed provider documents that an approved product does not adequately meet your medical needs. After a medical encounter, the provider determines whether to prescribe a compounded medication sourced through a licensed 503A pharmacy.
Optima’s compounded medication comes in a vial for injection with an insulin syringe, not a branded prefilled pen. Your provider explains your prescribed dose, and Optima’s vial-and-syringe injection training supplements those instructions. You should not change your dose or injection frequency without your provider’s direction.
You can receive an evaluation and follow-up through Texas telehealth or at Optima’s Tyler clinic. During follow-up, your provider can review your response and side effects before deciding whether your prescription needs adjustment. Compounded preparations are not FDA-approved, have not undergone FDA review for safety, effectiveness, or quality, and are not established as equivalent to approved products.
How soon might I notice results? Some people notice less hunger during early treatment, but weight changes vary and may take longer to measure. Your provider can assess progress as your dose changes.
Are weight-loss results guaranteed? No. Trials report averages across participants using FDA-approved products, and your response may differ.
How do compounded and branded products differ? FDA-approved products have standardized formulations and labeled dosing. A licensed provider may prescribe a patient-specific compounded preparation when an approved product does not adequately meet your documented medical needs, but compounded GLP-1 medications are not FDA-approved or established as equivalent to approved products.
What could rule out treatment? A provider needs to review your medical history, current medications, and pregnancy status before prescribing. A personal or family history of medullary thyroid cancer is one reason a provider may rule out these medications.
Optima Tyler’s consultation is the starting point for GLP-1 treatment in Texas. A licensed provider reviews your medical history, current medications, weight-related health concerns, and safety risks before deciding whether treatment is appropriate and which medication may fit your needs. If you are considering treatment, schedule a weight-loss consultation to discuss your eligibility and options.